Zenas BioPharma (ZBIO) Insider Patricia Allen Buys 18,500 Shares
Insider buying continues at ZBIO with Patricia Allen and others acquiring shares.
Reviewed by automated data checks against the source filing. How we make and check alerts
Patricia Allen bought 18,500 shares of Zenas BioPharma, Inc. ($ZBIO) on June 15, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $ZBIO is up 11.2% after 1 week, up 57.2% after 1 month and up 32.8% to date (from the $18.71 close on Jun 15, 2026).
ZBIO
Zenas BioPharma, Inc.
Key Points
- On June 15, 2026, Patricia Allen purchased 18,500 shares of ZBIO, joining other insiders in buying the stock.
- Shares of ZBIO traded around $18.58, with institutional investors like FMR LLC and Polar Capital Holdings PLC adjusting their positions.
- Analysts have mixed views on ZBIO, with Morgan Stanley maintaining a hold rating and Citigroup a buy rating.
Get $ZBIO trade alerts by text
We text you when insiders, Congress or big funds trade $ZBIO. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Zenas BioPharma, Inc. alert may contain errors. Disclosures
Patricia Allen, an insider at ZBIO, bought 18,500 shares on June 15, 2026. This purchase is part of a larger pattern of insider buying, as several other insiders also acquired shares on the same day.
Other Institutional Activity in ZBIO
FMR LLC increased its holdings by 1,377,745 shares, ending with 9,082,000 shares valued at approximately $177.6 million. Polar Capital Holdings PLC made a notable move, adding 1,490,835 shares to reach a total of 2,548,444 shares worth about $49.8 million. Meanwhile, NEA Management Company, LLC grew its position by 500,000 shares, bringing its total to 4,023,219 shares valued at roughly $78.7 million.
Zenas BioPharma, Inc. Stock Down 41.0%
Shares of ZBIO traded near $18.58. While specific financial metrics like market cap and P/E ratio aren't available, the stock's performance is closely watched by institutional investors and analysts.
Insider Buying and Selling at Zenas BioPharma, Inc.
On June 15, 2026, multiple insiders purchased shares of ZBIO. James Boylan, Patricia Allen, and Jason Raleigh Nunn each acquired 18,500 shares. Joseph Farmer, President and COO, bought 175,000 shares, while Lisa Von Moltke, Head of Research and Development and Chief Medical Officer, purchased 150,000 shares. Jennifer Fox, Chief Business Officer and CFO, acquired 125,000 shares. These transactions were not part of a pre-arranged trading plan.
Analysts Set New Price Targets
On May 14, 2026, Morgan Stanley maintained a hold rating with a $22 price target. Earlier, on March 17, 2026, Citigroup and Guggenheim both maintained buy ratings, with targets of $41 and $55, respectively. HC Wainwright & Co. reiterated a buy rating with a $44 target on February 10, 2026.
Bottom Line
Insider buying at ZBIO suggests confidence among company executives, though the transactions' timing may not reflect current market conditions. Institutional investors and analysts show varied opinions, indicating a complex investment landscape. As always, it's important to consider multiple factors when evaluating a stock's potential.
Related Filing Alerts
Source: Patricia Allen's Form 4 filing on $ZBIO (Jun 15, 2026). Find the original filing: ZBIO Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts